<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Jacobs, M.L.</title>
    <link>http://repub.eur.nl/res/aut/3775/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Glycaemic control and growth hormone in diabetes mellitus (Doctoral Thesis)</title>
      <link>http://repub.eur.nl/res/pub/18156/</link>
      <pubDate>1997-06-04T00:00:00Z</pubDate>
      <description></description>
    </item> <item>
      <title>Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus (Article)</title>
      <link>http://repub.eur.nl/res/pub/8715/</link>
      <pubDate>1997-01-01T00:00:00Z</pubDate>
      <description>The existing literature on serum insulin-like growth factor I (IGF-I)
          levels in insulin-dependent diabetes mellitus (IDDM) is conflicting. Free
          IGF-I may have greater physiological and clinical relevance than total
          IGF-I. Recently, a validated method has been developed to measure free
          IGF-I levels in the circulation. Serum free and total IGF-I, IGF-binding
          protein-1 (IGFBP-1), and IGFBP-3 levels were measured in 56
          insulin-treated IDDM patients and 52 healthy sex- and age-matched
          controls. Diabetic retinopathy was established by direct fundoscopy. In 54
          IDDM patients, the glomerular filtration rate (GFR) and effective renal
          plasma flow were calculated from the clearance rate of [125I]iothalamate
          and [131I]iodohippurate sodium. Fasting free IGF-I, total IGF-I, and
          IGFBP-3 levels were significantly lower in IDDM patients than in age- and
          sex-matched healthy controls (free IGF-I, P &lt; 0.005; total IGF-I, P &lt;
          0.001; IGFBP-3, P = 0.001), whereas IGFBP-1 levels were higher (P &lt;
          0.001). In IDDM subjects, decreases in free IGF-I, total IGF-I, and
          IGFBP-3 levels with age were observed (free IGF-I, r = -0.27 and P = 0.05;
          total IGF-I, r = -0.52 and P &lt; 0.001; IGFBP-3, r = -0.37 and P = 0.005).
          Free IGF-I was inversely related to fasting glucose in IDDM subjects (r =
          -0.35; P = 0.01), whereas the relationship between total IGF-I and fasting
          glucose did not reach significance (r = -0.27; P = 0.06). Age-adjusted
          free IGF-I levels were significantly higher (P &lt; 0.05) in IDDM subjects
          with retinopathy than in subjects without retinopathy after adjustment for
          age. Total IGF-I and IGFBP-3 levels were positively related to GFR (total
          IGF-I, r = 0.35 and P &lt; 0.05; IGFBP-3, r = 0.28 and P &lt; 0.05). Both of
          these differences lost significance after adjustment for age. Free IGF-I,
          total IGF-I, and IGFBP-3 levels were lower and IGFBP-1 levels were higher
          in insulin-treated IDDM subjects compared to those in age- and sex-matched
          controls. Free IGF-I, total IGF-I, and IGFBP-3 levels decreased
          significantly with age in IDDM subjects. Age-adjusted free IGF-I levels in
          subjects with diabetic retinopathy were higher than those in subjects
          without diabetic retinopathy. Total IGF-I and IGFBP-3 levels were
          positively related to GFR in IDDM subjects, but these relations were lost
          after adjustment for age. Measurement of serum free IGF-I levels in IDDM
          subjects did not have clear advantages compared to that of total IGF-I,
          IGFBP-1, and IGFBP-3 levels. Serum IGF-I and IGFBPs reflect their tissue
          concentrations to a various degree. Consequently, extrapolations
          concerning the pathogenetic role of the IGF/IGFBP system in the
          development of diabetic complications at the tissue level remain
          speculative.</description>
    </item>
  </channel>
</rss>